Ultomiris 300 mg/30mL
ravulizumab · SOLUTION, CONCENTRATE · Alexion Pharmaceuticals Inc.
Ultomiris is a solution, concentrate containing ravulizumab at 300 mg/30mL, taken intravenous. Manufactured by Alexion Pharmaceuticals Inc..
Key Facts
- Brand Name
- Ultomiris
- Generic Name
- ravulizumab
- NDC Code (Product)
25682-022- Manufacturer
- Alexion Pharmaceuticals Inc.
- Strength
- 300 mg/30mL
- Dosage Form
- SOLUTION, CONCENTRATE
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761108
- Drug Class
- Complement Inhibitor [EPC]
- Marketing Start
- 12/21/2018
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is Ultomiris used for?
Ultomiris contains ravulizumab. It is a solution, concentrate taken intravenous. Consult your doctor for specific uses.
Is Ultomiris a controlled substance?
Ultomiris is not classified as a controlled substance by the DEA.
What is the generic name for Ultomiris?
The generic name for Ultomiris is ravulizumab. There are no other listed brand versions of ravulizumab.
What is the NDC code for Ultomiris 300 mg/30mL?
The NDC (National Drug Code) for Ultomiris 300 mg/30mL is 25682-022, listed by Alexion Pharmaceuticals Inc..
Other Ultomiris Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)